Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baptiste Abbar

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
Frontiers in Cardiovascular Medicine|March 3, 2025
Case Report: Immune checkpoint-inhibitor related myotoxicity monitoring using a comprehensive cardiothoracic MRI approach: insights from a clinical caseSamia Boussouar, Etienne Charpentier, Baptiste Abbar, et al.
Therapie|December 13, 2021
Androgens, QT, sex and ventricular repolarization-a double-edged sword: A case seriesMelissa Y Y Moey, Marie Wilkin, Estelle Gandjbakhch, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancerSandra Assoun, Nathalie Theou-Anton, Marina Nguenang, et al.
Clinical Pharmacology and Therapeutics|June 16, 2025
Comedications Associated with Immune-Related Adverse Events from Immune-Checkpoint InhibitorsLéonard Laurent, Baptiste Abbar, Kevin Bihan, et al.
Cancers|August 26, 2022
Grade 3-4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational StudyNadia Guezour, Ghassen Soussi, Solenn Brosseau, et al.
Lung Cancer (Amsterdam, Netherlands)|July 4, 2021
Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trialArmelle Lavole, Julien Mazieres, Sophie Schneider, et al.
Annals of Intensive Care|March 8, 2017
Outcomes in elderly patients admitted to the intensive care unit with solid tumorsEdouard Auclin, Anaïs Charles-Nelson, Baptiste Abbar, et al.
Eclinicalmedicine|April 1, 2024
Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspectivePaul Gougis, Floriane Jochum, Baptiste Abbar, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 22, 2021
Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoringBenoit Llopis, Pascal Robidou, Nadine Tissot, et al.
Cancer Medicine|August 29, 2025
Vinorelbine With or Without Thiotepa for HER2-Negative Metastatic Breast Cancer: A Propensity Score AnalysisAurelia Robert, Paul Gougis, Elise Dumas, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Frontiers in Cardiovascular Medicine|March 3, 2025
Case Report: Immune checkpoint-inhibitor related myotoxicity monitoring using a comprehensive cardiothoracic MRI approach: insights from a clinical caseSamia Boussouar, Etienne Charpentier, Baptiste Abbar, et al.
Therapie|December 13, 2021
Androgens, QT, sex and ventricular repolarization-a double-edged sword: A case seriesMelissa Y Y Moey, Marie Wilkin, Estelle Gandjbakhch, et al.
Lung Cancer (Amsterdam, Netherlands)|May 18, 2019
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancerSandra Assoun, Nathalie Theou-Anton, Marina Nguenang, et al.
Clinical Pharmacology and Therapeutics|June 16, 2025
Comedications Associated with Immune-Related Adverse Events from Immune-Checkpoint InhibitorsLéonard Laurent, Baptiste Abbar, Kevin Bihan, et al.
Cancers|August 26, 2022
Grade 3-4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational StudyNadia Guezour, Ghassen Soussi, Solenn Brosseau, et al.
Lung Cancer (Amsterdam, Netherlands)|July 4, 2021
Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trialArmelle Lavole, Julien Mazieres, Sophie Schneider, et al.
Annals of Intensive Care|March 8, 2017
Outcomes in elderly patients admitted to the intensive care unit with solid tumorsEdouard Auclin, Anaïs Charles-Nelson, Baptiste Abbar, et al.
Eclinicalmedicine|April 1, 2024
Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspectivePaul Gougis, Floriane Jochum, Baptiste Abbar, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 22, 2021
Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoringBenoit Llopis, Pascal Robidou, Nadine Tissot, et al.
Cancer Medicine|August 29, 2025
Vinorelbine With or Without Thiotepa for HER2-Negative Metastatic Breast Cancer: A Propensity Score AnalysisAurelia Robert, Paul Gougis, Elise Dumas, et al.
Pageof 4